A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia

References

• Trouet A., Deprez-de Campenerre D., de Duve D. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature (New Biol.) 1972; 239: 110–12
   Web of Science ®Google Scholar
• Trouet A., Deprez-de Campenerre D., de Smedt-Malengreaux M., Atassi G. Experimental leukemia chemotherapy with a “lysosomotropic” Adriamycin-DNA complex. Europ. J. Cancer 1974; 10: 405–11
   PubMed Web of Science ®Google Scholar
• Trouet A., Sokal G. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: A review. Cancer Treat. Rep 1979; 63: 895–8
   PubMedGoogle Scholar
• Gahrton G., Björkholm M., Brenning G., Christenson I., Engstedt L., Franzén S., Gullbring B., Holm G., Högman C., Hörnsten P., Jameson S., Killander A., Simonsson-Lindemalm C., Lockner D., Lönnquist B., Mellstedt H., Palmblad J., Paul C., Pauli C., Peterson C., Reizenstein P., Simonsson B., Skárberg K.-O., Udén A.-M., Wadman B. Treatment of acute non-lymphoblastic leukemia in adults with daunorubicin-DNA complex; A preliminary report. Cancer Chemother. Pharmacol 1979; 2: 73–6
   PubMed Web of Science ®Google Scholar
• Paul C., Björkholm M., Engstedt L., Gahrton G., Hast R., Holm G., Killander A., Lantz B., Lockner D., Lönnquist B., Mellstedt H., Palmblad J., Peterson C., Simonsson B., Stalfelt A.-M., Udén A.-M., Wadman B., Öberg G. Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute non-lymphoblastic leukemia. Cancer Chemother. Pharmacol 1981; 6: 65–73
   PubMed Web of Science ®Google Scholar
• Paul C., Gahrton G., Peterson C. Effects of DNA-binding and prolonged infusion on the pharmacokinetics of anthracyclines. Anthracyclines and Cancer Therapy, H. H. Hanse. Excerpta Medica, Amsterdam 1983; 18–24
   Google Scholar
• Paul C., Liliemark J., Tidefelt U., Gahrton G., Peterson C. Pharmacokinetics of daunorubicir and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Therapeutic Drug Monitoring 1989; 11: 140–8
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M.-T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. Br. J. Haematol 1976; 33: 451–8
   PubMed Web of Science ®Google Scholar
• Öst À, Lagerlöf B., Sundström C., Lindström P., Gyllenhammer H., Engstedt L., Skoog L. A study of the reproducibility of the diagnostic criteria for acute leukemia. Scand. J. Haematol 1983; 31: 257–66
   PubMedGoogle Scholar
• Keating M. J., Smith T. L., Gehan E. A., McCredie K. B., Bodey G. P., Spitzer G., Hersh E., Gutterman J., Freireich E. J. Factors related to length of complete remission in adult acute leukemia. Cancer 1980; 45: 2017–29
   PubMed Web of Science ®Google Scholar
• Peto R., Pike M. C. Conservatism of the approximation {sigma}(O - E)<+>2</+> /E in the logrank test for survival data or tumor incidence data. Biometrics 1973; 29: 579
   PubMed Web of Science ®Google Scholar
• Peterson C., Gahrton G., Paul C. Transport and storage of anthracyclines in experimental systems and human leukemia. Anthracycline antibiotics in cancer chemotherapy, Muggia, Young, Carter. Martinus Nijhoff Publishers. 1982; 132
   Google Scholar
• Paul C., Baurain R., Gahrton G., Peterson C. Determination of daunorubicin and its main metabolites in plasma, urine and leukemic cells in patients with acute myeloblastic leukemia. Cancer Letters 1980; 9: 263–9
   PubMed Web of Science ®Google Scholar
• Rogers K., Carr B., Tökes Z. Cell surface mediated cytotoxicity of polymerbound Adriamycin against drug-resistance hepatocytes. Cancer Res 1983; 43: 2741–8
   PubMed Web of Science ®Google Scholar
• Paul C., Lönnqvist B., Gahrton G., Lockner D., Peterson C. Reducing the cardiotoxicity of anthracyclines by complex-binding to DNA. Report of three cases. Cancer 1981; 48: 1531–4
   PubMed Web of Science ®Google Scholar
• Yates J., Glidewell O., Wiernik P., Cooper M. R., Steinberg D., Dosilc H., Levy R., Hoagland C., Henry P., Gottlieb A., Cornell C., Berenberg J., Hutchison J. L., Raich P., Nissen N., Ellison R. R., Frelick R., James G. W., Falkson G., Silver R. T., Haurani F., Green M., Henderson E., Leone L., Holland J. F. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982; 60: 454–62
   PubMed Web of Science ®Google Scholar
• Legha S. S., Benjamin R. S., Macklay B., Ewer M., Wallace S., Valdivieso M. Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann. Intern. Med 1982; 96: 133–9
   PubMed Web of Science ®Google Scholar
• Mayer R. J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin. Oncol 1987; 14(4)384–96
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Winton E. F., Gordon D. S., Raney M. R., Go B., Meyer L. A randomized comparison of the postremission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial. Blood 1984; 63(5)1039–45
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Fiere D., Treille-Ritouet D., Adeleine P., Guyotat D., Sebban C., Vuvan H., Viala J. J. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: A randomized trial. Cancer treat. Rep 1987; 71(6)571–4
   PubMedGoogle Scholar
• Rees J. K. H., Swirsky D., Gray R. G., Hayhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 1986; 29: 1236–41
   Google Scholar